Research programme: RNA therapeutics - Arcturus Therapeutics/Janssen Pharmaceuticals

Drug Profile

Research programme: RNA therapeutics - Arcturus Therapeutics/Janssen Pharmaceuticals

Alternative Names: Human alpha-1 antitrypsin messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; Human cystic fibrosis transmembrane conductance messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; Human erythropoietin messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; Human factor IX messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; Human tumor protein p53 messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; LUNAR-101; LUNAR-102; LUNAR-CF; LUNAR-hepcidin messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; LUNAR-HPN; LUNAR-ornithine transcarbamylase messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; LUNAR-OTC; LUNAR-thrombopoietin messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; LUNAR-TPO

Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator Arcturus Therapeutics
  • Class MicroRNAs; RNA; Small interfering RNA
  • Mechanism of Action RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency; Amyloid polyneuropathy; Amyloidosis; Anaemia; Haemophilia B
  • Research Cancer; Cystic fibrosis; Inborn urea cycle disorders; Iron overload; Thrombocytopenia

Most Recent Events

  • 16 Mar 2016 Arcturus Therapeutics receives intent to grant notice from the European Patent Office for their unlocked nucleomonomer agent (UNA) Technology
  • 11 Jun 2015 Arcturus Therapeutics and Janssen Pharmaceuticals agree to co-develop and co-promote RNA therapeutics for specific diseases
  • 10 Nov 2014 Pharmacodynamics and Adverse events data from a preclinical trial in Anaemia released by Arcturus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top